ArticleScience signaling2020
Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.
Open access · greenAbstract read
In one paragraph
Article in Science signaling, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 61 citations in OpenAlex.
- TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity.Nature communications · 2026Article
- High‑Grade renal cell carcinoma with somatic BRCA2 mutation and biphasic morphology: an additional case expanding the morphological spectrum of an emerging RCC type.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Targeting epigenetic networks to overcome cisplatin resistance in ovarian cancer: from mechanisms to clinical translation.Journal of ovarian research · 2026Review
- The expanding roles of homologous recombination proteins in genome stability.The EMBO journal · 2026Review
- A single BRCA2 BRC repeat supports viability while multiple repeats ensure resilience under stress.bioRxiv : the preprint server for biology · 2026Article
- 5-Hydroxymethylcytosine: a key epigenetic mark in cancer and chemotherapy response.Epigenetics & chromatin · 2025Review
- PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation.Frontiers in cell and developmental biology · 2025Article
- AP endonuclease 1: Biological updates and advances in activity analysis.Methods in enzymology · 2024Article
- Inhibition of cytosine 5-hydroxymethylation during progression of cancer precursor lesions in the uterine cervix.PloS one · 2024Article
- The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance.Current topics in medicinal chemistry · 2024Review
- Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins.International journal of molecular sciences · 2023Article
- Mechanistic insight into AP-endonuclease 1 cleavage of abasic sites at stalled replication fork mimics.Nucleic acids research · 2023Article
- DNA Glycosylases Define the Outcome of Endogenous Base Modifications.International journal of molecular sciences · 2023Review
- circCIMT Silencing Promotes Cadmium-Induced Malignant Transformation of Lung Epithelial Cells Through the DNA Base Excision Repair Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Targeting epigenetic regulators to overcome drug resistance in cancers.Signal transduction and targeted therapy · 2023Review
- Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer.Frontiers in pharmacology · 2023Review
- 5hmC modification regulates R-loop accumulation in response to stress.Frontiers in psychiatry · 2023Article
- Review
- Acute deletion of TET enzymes results in aneuploidy in mouse embryonic stem cells through decreased expression of Khdc3.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Suhas S KharatMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0003-2283-7429
Xia DingMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0003-0388-5388
Divya SwaminathanMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-3722-1857
Akshey SureshMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Manish SinghMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Satheesh K SengodanMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Sandra BurkettMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-5476-4028
Hanna MarksMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-2514-5404
Chinmayi PamalaMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Yafeng HeMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0001-9099-8764
Stephen D FoxLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0003-0664-9970
Eugen C BuehlerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA.ORCID 0000-0001-7167-676X
Kathrin MueggeMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Scott E MartinDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA.
Shyam K SharanMouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. sharans@mail.nih.gov.ORCID 0000-0002-9333-870X
National Cancer Institute · USLeidos (United States) · USNational Center for Advancing Translational Sciences · US
Funding
Identification of genetic interactors of BRCA2ZIABC011311 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2010 to 2025
$13.2MFunctional Evaluation of BRCA2 Variants on TumorigenesisZIABC010387 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2009 to 2025
$12.5MIntramural NIH HHS ZIA BC010387Intramural NIH HHS ZIA BC011311
Abstract
Synthetic lethality between poly(ADP-ribose) polymerase (PARP) inhibition and
Indexed as
5-MethylcytosineAnimalsBreast NeoplasmsCell LineCell Line, TumorDeoxycytidineDNA-(Apurinic or Apyrimidinic Site) LyaseDNA ReplicationDrug Resistance, NeoplasmFemaleGenomic InstabilityHumansMiceMice, NudeNeoplasms, ExperimentalOvarian Neoplasms5-hydroxymethyl-2'-deoxycytidine5-MethylcytosineAPEX1 protein, humanDeoxycytidineDNA-(Apurinic or Apyrimidinic Site) LyaseolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.